s
s
s
Develop highly selective and sensitive PK and ADA assays for etanercept (Enbrel) using our range of ready-made antibodies.
Table 1. Antibodies Specific to Etanercept.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Etanercept |
HCA277 |
AbD25940_hIgG4Pro |
Human IgG4Pro1 HRP |
2.4 |
PK bridging ELISA |
|
Etanercept |
HCA276 |
AbD25939 |
Fab-FH2 |
3.2 |
PK bridging ELISA
|
|
Etanercept Fusion-region specific |
HCA279 |
AbD26183_hIgG1 |
Human IgG1 HRP |
14.8 |
PK ELISA |
* Affinity measured in the monovalent Fab format
1 IgG4 isotype with a mutation in the core hinge region that prevents the formation of IgG4 half molecules
2 Monovalent Fab antibody DYKDDDDK- and His-6-tags
The anti-etanercept inhibitory antibody binds to the p75 subunit of etanercept and blocks the binding of etanercept to its target, tumor necrosis factor alpha (TNFα). It is ideal for use in a bridging ELISA to develop pharmacokinetic (PK) assays to measure free drug, and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay.
The anti-etanercept non-inhibitory antibody binds to the p75 subunit of etanercept, but does not inhibit the binding of TNFα. It binds to both free etanercept and to etanercept bound to TNFα and can therefore be used in a bridging ELISA to develop PK assays to detect total drug (free, bound or partially bound).
This antibody specifically recognizes etanercept at the region of the fusion between p75 and the Fc domain of human IgG1. It binds to free etanercept and to etanercept in complex with TNFα. It does not bind to p75 (soluble TNFR2) or to human IgG1. It does not inhibit the binding of etanercept to TNFα. This product may be used as a detection antibody in a bridging ELISA to measure total etanercept very specifically.
Fig. 1. Etanercept PK bridging ELISA using antibodies HCA276 and HCA277P.
Schematic image of PK bridging ELISA measuring free drug. Capture antibody, Fab format (purple), fusion protein drug (gold-green), detection antibody, Ig format (blue), labeled with HRP
Fig. 2. Etanercept PK bridging ELISA using antibodies HCA276 and HCA279P
Schematic image of PK bridging ELISA measuring total drug. Capture antibody, Fab format (purple), fusion protein drug (gold-green), detection antibody, Ig format (blue), labeled with HRP
Fig. 3. Etanercept ADA bridging ELISA using antibody HCA277.
Schematic image of ADA bridging assay. Fusion protein drug as capture and detection reagent labeled with HRP (gold-green), fully human anti-drug antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.